Literature DB >> 2910248

Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system).

A Sardi1, M Workman, C Mojzisik, G Hinkle, C Nieroda, E W Martin.   

Abstract

Since 1986, 32 patients with metastatic colorectal cancer have undergone second-look radioimmunoguided surgery (RIGS system). The primary tumor was located in the right and transverse colon in 11 patients, left and sigmoid colon in 16, and rectum in five. The carcinoembryonic antigen level was elevated in 30 patients (94%); all patients underwent a computed tomographic scan of the abdomen and pelvis. The overall sensitivity of the computed tomographic scan was 41% (abdomen other than liver, 27%; liver, 58%; and pelvis, 22%). The RIGS system identified recurrent tumor in 81% of the patients. The most common site of metastasis was the liver (41%), independent of the primary location. Local/regional recurrences alone accounted for 40% of all recurrences. In six patients (18%), recurrent tumor was found only with the RIGS system. The RIGS system is more dependable in localizing clinically obscure metastases than other methods, and carcinoembryonic antigen testing remains the most accurate preoperative method to indicate suspected recurrences.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910248     DOI: 10.1001/archsurg.1989.01410010065014

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  12 in total

1.  Iodine-131 human-mouse chimeric Fab monoclonal antibody A7 guided surgery for colorectal cancer patients: a pilot study.

Authors:  K Yamamoto; K Kitamura; S Nishida; D Ichikawa; K Okamoto; T Yamaguchi; T Takahashi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.

Authors:  Duojiao Chen; Taylor M Parker; Poornima Bhat-Nakshatri; Xiaona Chu; Yunlong Liu; Yue Wang; Harikrishna Nakshatri
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

3.  Didactic review of 175 radionuclide-guided excisions of osteoid osteomas.

Authors:  M Wioland; A Sergent-Alaoui
Journal:  Eur J Nucl Med       Date:  1996-08

4.  A hand-held beta imaging probe for FDG.

Authors:  Bipin Singh; Brendan C Stack; Samta Thacker; Valeriy Gaysinskiy; Twyla Bartel; Val Lowe; Steven Cool; Gerald Entine; Vivek Nagarkar
Journal:  Ann Nucl Med       Date:  2012-12-11       Impact factor: 2.668

5.  Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.

Authors:  Peng Zou; Songbo Xu; Stephen P Povoski; Anna Wang; Morgan A Johnson; Edward W Martin; Vish Subramaniam; Ronald Xu; Duxin Sun
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

6.  Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody.

Authors:  C Curtet; J P Vuillez; G Daniel; G Aillet; A Chetanneau; J Visset; M Kremer; P Thédrez; J F Chatal
Journal:  Eur J Nucl Med       Date:  1990

7.  Evaluation of a technique for the intraoperative detection of a radiolabelled monoclonal antibody against colorectal cancer.

Authors:  W A Waddington; B R Davidson; A Todd-Pokropek; P B Boulos; M D Short
Journal:  Eur J Nucl Med       Date:  1991

8.  Detection of colorectal carcinomas by intraoperative RIS in addition to preoperative RIS: surgical and immunohistochemical findings.

Authors:  M Reuter; R Montz; K de Heer; H Schäfer; R Klapdor; K Desler; H W Schreiber
Journal:  Eur J Nucl Med       Date:  1992

9.  Candidate silencer elements for the human and mouse genomes.

Authors:  Naresh Doni Jayavelu; Ajay Jajodia; Arpit Mishra; R David Hawkins
Journal:  Nat Commun       Date:  2020-02-26       Impact factor: 14.919

10.  Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.

Authors:  B Wangberg; E Forssell-Aronsson; L E Tisell; O Nilsson; M Fjalling; H Ahlman
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.